Log in

NASDAQ:CBMG - Cellular Biomedicine Group Stock Price, Forecast & News

$17.49
+0.08 (+0.46 %)
(As of 12/8/2019 02:15 PM ET)
Today's Range
$17.36
Now: $17.49
$18.00
50-Day Range
$14.75
MA: $17.40
$18.78
52-Week Range
$10.98
Now: $17.49
$20.50
Volume63,978 shs
Average Volume56,538 shs
Market Capitalization$337.21 million
P/E RatioN/A
Dividend YieldN/A
Beta2.91
Cellular Biomedicine Group, Inc, a clinical stage biopharmaceutical company, develops therapies for cancer and degenerative diseases in Greater China. It focuses on developing and marketing cell-based therapies to treat various diseases, such as cancer and orthopedic diseases. The company develops treatments utilizing proprietary cell based technologies, including immune cell therapy for treating a range of cancer indications comprising technologies in chimeric antigen receptor modified T cells (CAR-T), a genetically modified T-cell receptors (TCRs), and next generation neoantigen-reactive tumor infiltrating lymphocytes; and human adipose-derived mesenchymal progenitor cells for the treatment of joint diseases. Read More…

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CBMG
CUSIPN/A
Phone408-973-7884

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$220,000.00
Book Value$4.63 per share

Profitability

Net Income$-38,930,000.00
Net Margins-17,921.62%

Miscellaneous

Employees193
Market Cap$337.21 million
Next Earnings Date2/18/2020 (Estimated)
OptionableOptionable

Receive CBMG News and Ratings via Email

Sign-up to receive the latest news and ratings for CBMG and its competitors with MarketBeat's FREE daily newsletter.


Cellular Biomedicine Group (NASDAQ:CBMG) Frequently Asked Questions

What is Cellular Biomedicine Group's stock symbol?

Cellular Biomedicine Group trades on the NASDAQ under the ticker symbol "CBMG."

How were Cellular Biomedicine Group's earnings last quarter?

Cellular Biomedicine Group Inc (NASDAQ:CBMG) released its earnings results on Tuesday, February, 19th. The biotechnology company reported ($0.45) earnings per share for the quarter, missing the consensus estimate of ($0.44) by $0.01. The biotechnology company had revenue of $0.03 million for the quarter, compared to the consensus estimate of $0.05 million. Cellular Biomedicine Group had a negative return on equity of 56.05% and a negative net margin of 17,921.62%. View Cellular Biomedicine Group's Earnings History.

When is Cellular Biomedicine Group's next earnings date?

Cellular Biomedicine Group is scheduled to release their next quarterly earnings announcement on Tuesday, February 18th 2020. View Earnings Estimates for Cellular Biomedicine Group.

What price target have analysts set for CBMG?

3 Wall Street analysts have issued 1 year price targets for Cellular Biomedicine Group's shares. Their forecasts range from $19.00 to $27.00. On average, they anticipate Cellular Biomedicine Group's stock price to reach $21.67 in the next year. This suggests a possible upside of 23.9% from the stock's current price. View Analyst Price Targets for Cellular Biomedicine Group.

What is the consensus analysts' recommendation for Cellular Biomedicine Group?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cellular Biomedicine Group in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cellular Biomedicine Group.

Has Cellular Biomedicine Group been receiving favorable news coverage?

Media headlines about CBMG stock have been trending extremely positive recently, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Cellular Biomedicine Group earned a news impact score of 5.0 on InfoTrie's scale. They also assigned news headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View News Stories for Cellular Biomedicine Group.

Are investors shorting Cellular Biomedicine Group?

Cellular Biomedicine Group saw a decline in short interest in the month of November. As of November 15th, there was short interest totalling 515,500 shares, a decline of 12.0% from the October 31st total of 585,800 shares. Based on an average daily trading volume, of 36,500 shares, the short-interest ratio is presently 14.1 days. Approximately 3.7% of the company's shares are sold short. View Cellular Biomedicine Group's Current Options Chain.

Who are some of Cellular Biomedicine Group's key competitors?

What other stocks do shareholders of Cellular Biomedicine Group own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cellular Biomedicine Group investors own include Crispr Therapeutics (CRSP), Exelixis (EXEL), Adaptimmune Therapeutics (ADAP), Editas Medicine (EDIT), Fate Therapeutics (FATE), Nektar Therapeutics (NKTR), Novavax (NVAX), Viewray (VRAY), Anthera Pharmaceuticals (ANTH) and ACADIA Pharmaceuticals (ACAD).

Who are Cellular Biomedicine Group's key executives?

Cellular Biomedicine Group's management team includes the folowing people:
  • Mr. Bizuo Liu, CEO, CFO & Director (Age 54)
  • Dr. Yihong Yao, Chief Scientific Officer (Age 51)
  • Mr. Andrew K. Chan, Chief Legal Officer, Gen. Counsel, Sr. VP of Corp. Bus. Devel. & Sec. (Age 61)
  • Dr. Li Zhang, Chief Production Officer
  • Derrick C. Li, Head of Strategy & Investor Relations

Who are Cellular Biomedicine Group's major shareholders?

Cellular Biomedicine Group's stock is owned by many different of retail and institutional investors. Top institutional investors include Sumitomo Mitsui Trust Holdings Inc. (2.90%), Nikko Asset Management Americas Inc. (2.90%), State Street Corp (1.13%), Russell Investments Group Ltd. (0.24%) and Barclays PLC (0.03%). Company insiders that own Cellular Biomedicine Group stock include Andrew K Chan, Tony Liu, Wen Tao Liu and Yihong Yao. View Institutional Ownership Trends for Cellular Biomedicine Group.

Which institutional investors are selling Cellular Biomedicine Group stock?

CBMG stock was sold by a variety of institutional investors in the last quarter, including Barclays PLC. View Insider Buying and Selling for Cellular Biomedicine Group.

Which institutional investors are buying Cellular Biomedicine Group stock?

CBMG stock was acquired by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Sumitomo Mitsui Trust Holdings Inc., Nikko Asset Management Americas Inc. and State Street Corp. Company insiders that have bought Cellular Biomedicine Group stock in the last two years include Andrew K Chan, Tony Liu and Yihong Yao. View Insider Buying and Selling for Cellular Biomedicine Group.

How do I buy shares of Cellular Biomedicine Group?

Shares of CBMG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Cellular Biomedicine Group's stock price today?

One share of CBMG stock can currently be purchased for approximately $17.49.

How big of a company is Cellular Biomedicine Group?

Cellular Biomedicine Group has a market capitalization of $337.21 million and generates $220,000.00 in revenue each year. The biotechnology company earns $-38,930,000.00 in net income (profit) each year or ($2.04) on an earnings per share basis. Cellular Biomedicine Group employs 193 workers across the globe.View Additional Information About Cellular Biomedicine Group.

What is Cellular Biomedicine Group's official website?

The official website for Cellular Biomedicine Group is http://www.cellbiomedgroup.com/.

How can I contact Cellular Biomedicine Group?

Cellular Biomedicine Group's mailing address is 19925 STEVENS CREEK BLVD. SUITE 100, CUPERTINO CA, 95014. The biotechnology company can be reached via phone at 408-973-7884 or via email at [email protected]


MarketBeat Community Rating for Cellular Biomedicine Group (NASDAQ CBMG)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  175 (Vote Outperform)
Underperform Votes:  196 (Vote Underperform)
Total Votes:  371
MarketBeat's community ratings are surveys of what our community members think about Cellular Biomedicine Group and other stocks. Vote "Outperform" if you believe CBMG will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CBMG will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/8/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel